The ABPI and the Department of Health are now beginning in earnest discussions about how we make value-based pricing work for patients, the NHS and industry. As Stephen Whitehead blogged three weeks ago, this is good news but there is a lot of work to be done.
Getting the policy right will not be simple. It will be important to take on board lots of different perspectives particularly from patients and the charities who support them. The ABPI looks forward to hearing their views as we take forward discussions with the Department of Health.
ABPI Press OfficeTel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811 Email: email@example.com
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.